Document is current
Any future updates will be listed below
-
Authors
Smeland, Olav B. https://orcid.org/0000-0002-3761-5215
Kutrolli, Gleda https://orcid.org/0000-0001-6602-2622
Bahrami, Shahram https://orcid.org/0000-0002-8179-2788
Fominykh, Vera https://orcid.org/0000-0001-5490-2390
Parker, Nadine https://orcid.org/0000-0002-8369-0152
Fuhrer, Julian https://orcid.org/0000-0001-6286-5614
Hindley, Guy F. L. https://orcid.org/0000-0003-1666-4701
Rødevand, Linn https://orcid.org/0000-0001-5967-6601
Jaholkowski, Piotr https://orcid.org/0000-0001-9408-3107
Tesfaye, Markos https://orcid.org/0000-0002-3351-701X
Parekh, Pravesh https://orcid.org/0000-0002-1930-1167
Elvsåshagen, Torbjørn https://orcid.org/0000-0001-9991-1610
Grotzinger, Andrew D. https://orcid.org/0000-0001-7852-9244
Steen, Nils Eiel https://orcid.org/0000-0001-6442-1179
van der Meer, Dennis
O’Connell, Kevin S.
Djurovic, Srdjan https://orcid.org/0000-0002-8140-8061
Dale, Anders M. https://orcid.org/0000-0002-6126-2966
Shadrin, Alexey A.
Frei, Oleksandr https://orcid.org/0000-0002-6427-2625
Andreassen, Ole A. https://orcid.org/0000-0002-4461-3568
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 12 September 2025
First Online: 11 November 2025
Competing interests
: O.A.A. has received speaker’s honoraria from Lundbeck, Sunovion, Takeda and Janssen and is a consultant for Cortechs.ai. A.M.D. is a founder of and holds equity interest in CorTechs Labs and serves on its scientific advisory board. He is also a member of the Scientific Advisory Board of Healthlytix and receives research funding from General Electric Healthcare. The terms of these arrangements have been reviewed and approved by the University of California, San Diego, in accordance with its conflict-of-interest policies. T.E. is a consultant to Cumulus and Sumitomo Pharma and received speaker’s honoraria from Lundbeck and Janssen Cilag. The other authors declare no competing interests.
